United States
Securities and Exchange Commission
Washington, D.C. 20549
Schedule 13G
(Rule 13d-102)
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
Stereotaxis, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
85916J102
(CUSIP Number)
December 31, 2007
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[Check one]
o Rule 13d-1(b)
o Rule 13d-1(c)
x Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosure provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|
CUSIP No. 85916J102 |
SCHEDULE 13G |
Page 1 of 20 |
|
(1) Names of reporting persons. |
Middleton McNeil Retirement Trust |
|
I.R.S. identification Nos. of above persons (entities only). |
|
|
(2) Check the appropriate box if a member of a group |
(a) |
|
(see instructions) |
(b) x |
|
(3) SEC use only. |
|
|
(4) Citizenship or place of organization. |
California |
|
Number of shares beneficially owned by each reporting person with: |
|
|
(5) Sole voting power. |
797 |
|
(6) Shared voting power. |
0 |
|
(7) Sole dispositive power. |
797 |
|
(8) Shared dispositive power. |
0 |
|
(9) Aggregate amount beneficially owned by each reporting person. |
797 Please see Attachment A |
|
(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions). |
|
|
(11) Percent of class represented by amount in Row (9). |
0.0% Please see Attachment A |
|
(12) Type of reporting person (see instructions). |
OO |
|
(1) Names of reporting persons. |
Sanderling Ventures Management V |
|
I.R.S. identification Nos. of above persons (entities only). |
|
|
(2) Check the appropriate box if a member of a group |
(a) |
|
(see instructions) |
(b) x |
|
(3) SEC use only. |
|
|
(4) Citizenship or place of organization. |
California |
|
Number of shares beneficially owned by each reporting person with: |
|
|
(5) Sole voting power. |
2,724 |
|
(6) Shared voting power. |
0 |
|
(7) Sole dispositive power. |
2,724 |
|
(8) Shared dispositive power. |
0 |
|
(9) Aggregate amount beneficially owned by each reporting person. |
2,724 Please see Attachment A |
|
(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions). |
|
|
(11) Percent of class represented by amount in Row (9). |
0.0% Please see Attachment A |
|
(12) Type of reporting person (see instructions). |
PN |
|
CUSIP No. 85916J102 |
SCHEDULE 13G |
Page 2 of 20 |
|
(1) Names of reporting persons. |
Sanderling VI Beteiligungs GmbH & Co. KG |
|
I.R.S. identification Nos. of above persons (entities only). |
|
|
(2) Check the appropriate box if a member of a group |
(a) |
|
(see instructions) |
(b) x |
|
(3) SEC use only. |
|
|
(4) Citizenship or place of organization. |
Germany |
|
Number of shares beneficially owned by each reporting person with: |
|
|
(5) Sole voting power. |
8,128 |
|
(6) Shared voting power. |
0 |
|
(7) Sole dispositive power. |
8,128 |
|
(8) Shared dispositive power. |
0 |
|
(9) Aggregate amount beneficially owned by each reporting person. |
8,128 Please see Attachment A |
|
(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions). |
|
|
(11) Percent of class represented by amount in Row (9). |
0.0% Please see Attachment A |
|
(12) Type of reporting person (see instructions). |
PN |
|
(1) Names of reporting persons. |
Sanderling VI Limited Partnership |
|
I.R.S. identification Nos. of above persons (entities only). |
|
|
(2) Check the appropriate box if a member of a group |
(a) |
|
(see instructions) |
(b) x |
|
(3) SEC use only. |
|
|
(4) Citizenship or place of organization. |
Cayman Islands |
|
Number of shares beneficially owned by each reporting person with: |
|
|
(5) Sole voting power. |
9,684 |
|
(6) Shared voting power. |
0 |
|
(7) Sole dispositive power. |
9,684 |
|
(8) Shared dispositive power. |
0 |
|
(9) Aggregate amount beneficially owned by each reporting person. |
9,684 Please see Attachment A |
|
(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions). |
|
|
(11) Percent of class represented by amount in Row (9). |
0.0% Please see Attachment A |
|
(12) Type of reporting person (see instructions). |
PN |
|
CUSIP No. 85916J102 |
SCHEDULE 13G |
Page 3 of 20 |
|
(1) Names of reporting persons. |
Sanderling Ventures Management VI |
|
I.R.S. identification Nos. of above persons (entities only). |
|
|
(2) Check the appropriate box if a member of a group |
(a) |
|
(see instructions) |
(b) x |
|
(3) SEC use only. |
|
|
(4) Citizenship or place of organization. |
California |
|
Number of shares beneficially owned by each reporting person with: |
|
|
(5) Sole voting power. |
1,149 |
|
(6) Shared voting power. |
0 |
|
(7) Sole dispositive power. |
1,149 |
|
(8) Shared dispositive power. |
0 |
|
(9) Aggregate amount beneficially owned by each reporting person. |
1,149 Please see Attachment A |
|
(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions). |
|
|
(11) Percent of class represented by amount in Row (9). |
0.0% Please see Attachment A |
|
(12) Type of reporting person (see instructions). |
PN |
|
(1) Names of reporting persons. |
Sanderling IV Biomedical Co-Investment Fund, L.P. |
|
I.R.S. identification Nos. of above persons (entities only). |
|
|
(2) Check the appropriate box if a member of a group |
(a) |
|
(see instructions) |
(b) x |
|
(3) SEC use only. |
|
|
(4) Citizenship or place of organization. |
California |
|
Number of shares beneficially owned by each reporting person with: |
|
|
(5) Sole voting power. |
542,238 |
|
(6) Shared voting power. |
0 |
|
(7) Sole dispositive power. |
542,238 |
|
(8) Shared dispositive power. |
0 |
|
(9) Aggregate amount beneficially owned by each reporting person. |
542,238 Please see Attachment A |
|
(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions). |
|
|
(11) Percent of class represented by amount in Row (9). |
1.5% Please see Attachment A |
|
(12) Type of reporting person (see instructions). |
PN |
|
CUSIP No. 85916J102 |
SCHEDULE 13G |
Page 4 of 20 |
|
(1) Names of reporting persons. |
Sanderling Venture Partners IV Co-Investment Fund, L.P. |
|
I.R.S. identification Nos. of above persons (entities only). |
|
|
(2) Check the appropriate box if a member of a group |
(a) |
|
(see instructions) |
(b) x |
|
(3) SEC use only. |
|
|
(4) Citizenship or place of organization. |
California |
|
Number of shares beneficially owned by each reporting person with: |
|
|
(5) Sole voting power. |
224,515 |
|
(6) Shared voting power. |
0 |
|
(7) Sole dispositive power. |
224,515 |
|
(8) Shared dispositive power. |
0 |
|
(9) Aggregate amount beneficially owned by each reporting person. |
224,515 Please see Attachment A |
|
(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions). |
|
|
(11) Percent of class represented by amount in Row (9). |
0.6% Please see Attachment A |
|
(12) Type of reporting person (see instructions). |
PN |
|
(1) Names of reporting persons. |
Sanderling Venture Partners V Co-Investment Fund, L.P. |
|
I.R.S. identification Nos. of above persons (entities only). |
|
|
(2) Check the appropriate box if a member of a group |
(a) |
|
(see instructions) |
(b) x |
|
(3) SEC use only. |
|
|
(4) Citizenship or place of organization. |
California |
|
Number of shares beneficially owned by each reporting person with: |
|
|
(5) Sole voting power. |
702,407 |
|
(6) Shared voting power. |
0 |
|
(7) Sole dispositive power. |
702,407 |
|
(8) Shared dispositive power. |
0 |
|
(9) Aggregate amount beneficially owned by each reporting person. |
702,407 Please see Attachment A |
|
(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions). |
|
|
(11) Percent of class represented by amount in Row (9). |
1.9% Please see Attachment A |
|
(12) Type of reporting person (see instructions). |
PN |
|
CUSIP No. 85916J102 |
SCHEDULE 13G |
Page 5 of 20 |
|
(1) Names of reporting persons. |
Sanderling V Beteiligungs GmbH & Co. KG |
|
I.R.S. identification Nos. of above persons (entities only). |
|
|
(2) Check the appropriate box if a member of a group |
(a) |
|
(see instructions) |
(b) x |
|
(3) SEC use only. |
|
|
(4) Citizenship or place of organization. |
Germany |
|
Number of shares beneficially owned by each reporting person with: |
|
|
(5) Sole voting power. |
114,536 |
|
(6) Shared voting power. |
0 |
|
(7) Sole dispositive power. |
114,536 |
|
(8) Shared dispositive power. |
0 |
|
(9) Aggregate amount beneficially owned by each reporting person. |
114,536 Please see Attachment A |
|
(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions). |
|
|
(11) Percent of class represented by amount in Row (9). |
0.3% Please see Attachment A |
|
(12) Type of reporting person (see instructions). |
PN |
|
(1) Names of reporting persons. |
Sanderling V Limited Partnership |
|
I.R.S. identification Nos. of above persons (entities only). |
|
|
(2) Check the appropriate box if a member of a group |
(a) |
|
(see instructions) |
(b) x |
|
(3) SEC use only. |
|
|
(4) Citizenship or place of organization. |
Cayman Islands |
|
Number of shares beneficially owned by each reporting person with: |
|
|
(5) Sole voting power. |
123,572 |
|
(6) Shared voting power. |
0 |
|
(7) Sole dispositive power. |
123,572 |
|
(8) Shared dispositive power. |
0 |
|
(9) Aggregate amount beneficially owned by each reporting person. |
123,572 Please see Attachment A |
|
(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions). |
|
|
(11) Percent of class represented by amount in Row (9). |
0.3% Please see Attachment A |
|
(12) Type of reporting person (see instructions). |
PN |
|
CUSIP No. 85916J102 |
SCHEDULE 13G |
Page 6 of 20 |
|
(1) Names of reporting persons. |
Sanderling V Biomedical Co-Investment Fund, L.P. |
|
I.R.S. identification Nos. of above persons (entities only). |
|
|
(2) Check the appropriate box if a member of a group |
(a) |
|
(see instructions) |
(b) x |
|
(3) SEC use only. |
|
|
(4) Citizenship or place of organization. |
California |
|
Number of shares beneficially owned by each reporting person with: |
|
|
(5) Sole voting power. |
412,018 |
|
(6) Shared voting power. |
0 |
|
(7) Sole dispositive power. |
412,018 |
|
(8) Shared dispositive power. |
0 |
|
(9) Aggregate amount beneficially owned by each reporting person. |
412,018 Please see Attachment A |
|
(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions). |
|
|
(11) Percent of class represented by amount in Row (9). |
1.1% Please see Attachment A |
|
(12) Type of reporting person (see instructions). |
PN |
|
(1) Names of reporting persons. |
Sanderling Venture Partners II, L.P. |
|
I.R.S. identification Nos. of above persons (entities only). |
|
|
(2) Check the appropriate box if a member of a group |
(a) |
|
(see instructions) |
(b) x |
|
(3) SEC use only. |
|
|
(4) Citizenship or place of organization. |
California |
|
Number of shares beneficially owned by each reporting person with: |
|
|
(5) Sole voting power. |
781,351 |
|
(6) Shared voting power. |
0 |
|
(7) Sole dispositive power. |
781,351 |
|
(8) Shared dispositive power. |
0 |
|
(9) Aggregate amount beneficially owned by each reporting person. |
781,351 Please see Attachment A |
|
(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions). |
|
|
(11) Percent of class represented by amount in Row (9). |
2.1% Please see Attachment A |
|
(12) Type of reporting person (see instructions). |
PN |
|
CUSIP No. 85916J102 |
SCHEDULE 13G |
Page 7 of 20 |
|
(1) Names of reporting persons. |
Sanderling Management 401(k) Plan |
|
I.R.S. identification Nos. of above persons (entities only). |
|
|
(2) Check the appropriate box if a member of a group |
(a) |
|
(see instructions) |
(b) x |
|
(3) SEC use only. |
|
|
(4) Citizenship or place of organization. |
California |
|
Number of shares beneficially owned by each reporting person with: |
|
|
(5) Sole voting power. |
15,000 |
|
(6) Shared voting power. |
0 |
|
(7) Sole dispositive power. |
15,000 |
|
(8) Shared dispositive power. |
0 |
|
(9) Aggregate amount beneficially owned by each reporting person. |
15,000 Please see Attachment A |
|
(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions). |
|
|
(11) Percent of class represented by amount in Row (9). |
0.0% Please see Attachment A |
|
(12) Type of reporting person (see instructions). |
PN |
|
(1) Names of reporting persons. |
Sanderling Venture Partners VI Co-Investment Fund, L.P. |
|
I.R.S. identification Nos. of above persons (entities only). |
|
|
(2) Check the appropriate box if a member of a group |
(a) |
|
(see instructions) |
(b) x |
|
(3) SEC use only. |
|
|
(4) Citizenship or place of organization. |
California |
|
Number of shares beneficially owned by each reporting person with: |
|
|
(5) Sole voting power. |
419,988 |
|
(6) Shared voting power. |
0 |
|
(7) Sole dispositive power. |
419,988 |
|
(8) Shared dispositive power. |
0 |
|
(9) Aggregate amount beneficially owned by each reporting person. |
419,988 Please see Attachment A |
|
(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions). |
|
|
(11) Percent of class represented by amount in Row (9). |
1.1% Please see Attachment A |
|
(12) Type of reporting person (see instructions). |
PN |
|
CUSIP No. 85916J102 |
SCHEDULE 13G |
Page 8 of 20 |
|
(1) Names of reporting persons. |
Fred A. Middleton |
|
I.R.S. identification Nos. of above persons (entities only). |
|
|
(2) Check the appropriate box if a member of a group |
(a) |
|
(see instructions) |
(b) x |
|
(3) SEC use only. |
|
|
(4) Citizenship or place of organization. |
United States of America |
|
Number of shares beneficially owned by each reporting person with: |
|
|
(5) Sole voting power. |
227,086 |
|
(6) Shared voting power. |
3,358,107 |
|
(7) Sole dispositive power. |
227,086 |
|
(8) Shared dispositive power. |
3,358,107 |
|
(9) Aggregate amount beneficially owned by each reporting person. |
3,585,193 Please see Attachment A |
|
(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions). |
|
|
(11) Percent of class represented by amount in Row (9). |
9.7% Please see Attachment A |
|
(12) Type of reporting person (see instructions). |
IN |
|
(1) Names of reporting persons. |
Robert G. McNeil |
|
I.R.S. identification Nos. of above persons (entities only). |
|
|
(2) Check the appropriate box if a member of a group |
(a) |
|
(see instructions) |
(b) x |
|
(3) SEC use only. |
|
|
(4) Citizenship or place of organization. |
United States of America |
|
Number of shares beneficially owned by each reporting person with: |
|
|
(5) Sole voting power. |
60,173 |
|
(6) Shared voting power. |
3,358,107 |
|
(7) Sole dispositive power. |
60,173 |
|
(8) Shared dispositive power. |
3,358,107 |
|
(9) Aggregate amount beneficially owned by each reporting person. |
3,418,280 Please see Attachment A |
|
(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions). |
|
|
(11) Percent of class represented by amount in Row (9). |
9.2% Please see Attachment A |
|
(12) Type of reporting person (see instructions). |
IN |
|
CUSIP No. 85916J102 |
SCHEDULE 13G |
Page 9 of 20 |
|
(1) Names of reporting persons. |
Timothy C. Mills |
|
I.R.S. identification Nos. of above persons (entities only). |
|
|
(2) Check the appropriate box if a member of a group |
(a) |
|
(see instructions) |
(b) x |
|
(3) SEC use only. |
|
|
(4) Citizenship or place of organization. |
United States of America |
|
Number of shares beneficially owned by each reporting person with: |
|
|
(5) Sole voting power. |
90,277 |
|
(6) Shared voting power. |
1,508,880 |
|
(7) Sole dispositive power. |
90,277 |
|
(8) Shared dispositive power. |
1,508,880 |
|
(9) Aggregate amount beneficially owned by each reporting person. |
1,599,157 Please see Attachment A |
|
(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions). |
|
|
(11) Percent of class represented by amount in Row (9). |
4.3% Please see Attachment A |
|
(12) Type of reporting person (see instructions). |
IN |
|
(1) Names of reporting persons. |
Timothy J. Wollaeger |
|
I.R.S. identification Nos. of above persons (entities only). |
|
|
(2) Check the appropriate box if a member of a group |
(a) |
|
(see instructions) |
(b) x |
|
(3) SEC use only. |
|
|
(4) Citizenship or place of organization. |
United States of America |
|
Number of shares beneficially owned by each reporting person with: |
|
|
(5) Sole voting power. |
0 |
|
(6) Shared voting power. |
1,508,880 |
|
(7) Sole dispositive power. |
0 |
|
(8) Shared dispositive power. |
1,508,880 |
|
(9) Aggregate amount beneficially owned by each reporting person. |
1,508,880 Please see Attachment A |
|
(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions). |
|
|
(11) Percent of class represented by amount in Row (9). |
4.1% Please see Attachment A |
|
(12) Type of reporting person (see instructions). |
IN |
|
CUSIP No. 85916J102 |
SCHEDULE 13G |
Page 10 of 20 |
|
(1) Names of reporting persons. |
Paul A. Grayson |
|
I.R.S. identification Nos. of above persons (entities only). |
|
|
(2) Check the appropriate box if a member of a group |
(a) |
|
(see instructions) |
(b) x |
|
(3) SEC use only. |
|
|
(4) Citizenship or place of organization. |
United States of America |
|
Number of shares beneficially owned by each reporting person with: |
|
|
(5) Sole voting power. |
0 |
|
(6) Shared voting power. |
153,209 |
|
(7) Sole dispositive power. |
0 |
|
(8) Shared dispositive power. |
153,209 |
|
(9) Aggregate amount beneficially owned by each reporting person. |
153,209 Please see Attachment A |
|
(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions). |
|
|
(11) Percent of class represented by amount in Row (9). |
0.4% Please see Attachment A |
|
(12) Type of reporting person (see instructions). |
IN |
|
CUSIP No. 85916J102 |
SCHEDULE 13G |
Page 11 of 20 |
Item 1.
|
(a) |
Name of issuer: |
Stereotaxis, Inc.
|
(b) |
Address of issuer’s principal executive offices: |
4320 Forest Park Avenue, Suite 100
St. Louis, MO 63108
Item 2.
|
(a) |
Name of person filing: |
Middleton McNeil Retirement Trust
Sanderling Ventures Management V
Sanderling VI Beteiligungs GmbH & Co. KG
Sanderling VI Limited Partnership
Sanderling Ventures Management VI
Sanderling IV Biomedical Co-Investment Fund, L.P.
Sanderling Venture Partners IV Co-Investment Fund, L.P.
Sanderling Venture Partners V Co-Investment Fund, L.P.
Sanderling V Beteiligungs GmbH & Co. KG
Sanderling V Limited Partnership
Sanderling V Biomedical Co-Investment Fund, L.P.
Sanderling Venture Partners II, L.P.
Sanderling Management 401(k) Plan
Sanderling Venture Partners VI Co-Investment Fund, L.P.
Fred A. Middleton
Robert G. McNeil
Timothy C. Mills
Timothy J. Wollaeger
Paul A. Grayson
The foregoing persons, sometimes collectively referred to herein as the “Reporting Persons,” have entered into a Joint filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit A (which is incorporated herein by reference), pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.
|
(b) |
Address of principal business office or, if none, residence: |
The address of the business office of each Reporting Person is:
c/o Sanderling Ventures
400 South El Camino Real
Suite 1200
San Mateo, California 94402-1708
|
CUSIP No. 85916J102 |
SCHEDULE 13G |
Page 12 of 20 |
|
(c) |
Citizenship: |
|
|
Middleton McNeil Retirement Trust |
California |
|
|
Sanderling Ventures Management V |
California |
|
|
Sanderling VI Beteiligungs GmbH & Co. KG |
Germany |
|
|
Sanderling VI Limited Partnership |
Cayman Islands |
|
|
Sanderling Ventures Management VI |
California |
|
|
Sanderling IV Biomedical Co-Investment Fund, L.P. |
California |
|
|
Sanderling Venture Partners IV Co-Investment Fund, L.P. |
California |
|
|
Sanderling Venture Partners V Co-Investment Fund, L.P. |
California |
|
|
Sanderling V Beteiligungs GmbH & Co. KG |
Germany |
|
|
Sanderling V Limited Partnership |
Cayman Islands |
|
|
Sanderling V Biomedical Co-Investment Fund, L.P. |
California |
|
|
Sanderling Venture Partners II, L.P. |
California |
|
|
Sanderling Management 401(k) Plan |
California |
|
|
Sanderling Venture Partners VI Co-Investment Fund, L.P. |
California |
|
|
Fred A. Middleton |
United States of America |
|
|
Robert G. McNeil |
United States of America |
|
|
Timothy C. Mills |
United States of America |
|
|
Timothy J. Wollaeger |
United States of America |
|
|
Paul A. Grayson |
United States of America |
|
(d) |
Title of class of securities: |
Common Stock, par value $0.001 per share, of Stereotaxis, Inc.
|
(e) |
CUSIP No.: |
85916J102
Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
|
(a) |
o |
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). |
|
|
|
|
|
(b) |
o |
Bank as defined in section 3(a)(6) of the of the Act (15 U.S.C. 78c). |
|
|
|
|
|
(c) |
o |
Insurance company as defined in section 3(a)(19) of the of the Act (15 U.S.C. 78c). |
|
|
|
|
|
(d) |
o |
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). |
|
|
|
|
|
(e) |
o |
An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); |
|
|
|
|
|
(f) |
o |
An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); |
|
|
|
|
|
(g) |
o |
A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G). |
|
|
|
|
|
(h) |
o |
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); |
|
|
|
|
|
CUSIP No. 85916J102 |
SCHEDULE 13G |
Page 13 of 20 |
|
(i) |
o |
A church plan that is excluded from the definition of an investment company |
|
|
|
under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); |
|
|
|
|
|
(j) |
o |
Group, in accordance with §240.13d-1(b)(1)(ii)(J). |
Item 4. Ownership
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
|
(a) |
Amount beneficially owned: |
|
|
Middleton McNeil Retirement Trust |
797 |
|
|
Sanderling Ventures Management V |
2,724 |
|
|
Sanderling VI Beteiligungs GmbH & Co. KG |
8,128 |
|
|
Sanderling VI Limited Partnership |
9,684 |
|
|
Sanderling Ventures Management VI |
1,149 |
|
|
Sanderling IV Biomedical Co-Investment Fund, L.P. |
542,238 |
|
|
Sanderling Venture Partners IV Co-Investment Fund, L.P. |
224,515 |
|
|
Sanderling Venture Partners V Co-Investment Fund, L.P. |
702,407 |
|
|
Sanderling V Beteiligungs GmbH & Co. KG |
114,536 |
|
|
Sanderling V Limited Partnership |
123,572 |
|
|
Sanderling V Biomedical Co-Investment Fund, L.P. |
412,018 |
|
|
Sanderling Venture Partners II, L.P. |
781,351 |
|
|
Sanderling Management 401(k) Plan |
15,000 |
|
|
Sanderling Venture Partners VI Co-Investment Fund, L.P. |
419,988 |
|
|
Fred A. Middleton |
3,585,193 |
|
|
Robert G. McNeil |
3,418,280 |
|
|
Timothy C. Mills |
1,599,157 |
|
|
Timothy J. Wollaeger |
1,508,880 |
|
|
Paul A. Grayson |
153,209 |
|
(b) |
Percent of class: |
|
|
Middleton McNeil Retirement Trust |
0.0% |
|
|
Sanderling Ventures Management V |
0.0% |
|
|
Sanderling VI Beteiligungs GmbH & Co. KG |
0.0% |
|
|
Sanderling VI Limited Partnership |
0.0% |
|
|
Sanderling Ventures Management VI |
0.0% |
|
|
Sanderling IV Biomedical Co-Investment Fund, L.P. |
1.5% |
|
|
Sanderling Venture Partners IV Co-Investment Fund, L.P. |
0.6% |
|
|
Sanderling Venture Partners V Co-Investment Fund, L.P. |
1.9% |
|
|
Sanderling V Beteiligungs GmbH & Co. KG |
0.3% |
|
|
Sanderling V Limited Partnership |
0.3% |
|
|
Sanderling V Biomedical Co-Investment Fund, L.P. |
1.1% |
|
|
Sanderling Venture Partners II, L.P. |
2.1% |
|
|
Sanderling Management 401(k) Plan |
0.0% |
|
|
Sanderling Venture Partners VI Co-Investment Fund, L.P. |
1.1% |
|
|
Fred A. Middleton |
9.7% |
|
|
Robert G. McNeil |
9.2% |
|
|
Timothy C. Mills |
4.3% |
|
|
Timothy J. Wollaeger |
4.1% |
|
|
Paul A. Grayson |
0.4% |
|
CUSIP No. 85916J102 |
SCHEDULE 13G |
Page 14 of 20 |
|
(c) |
Number of shares as to which such person has: |
|
|
(i) Sole power to vote or to direct the vote: |
|
|
Middleton McNeil Retirement Trust |
797 |
|
|
Sanderling Ventures Management V |
2,724 |
|
|
Sanderling VI Beteiligungs GmbH & Co. KG |
8,128 |
|
|
Sanderling VI Limited Partnership |
9,684 |
|
|
Sanderling Ventures Management VI |
1,149 |
|
|
Sanderling IV Biomedical Co-Investment Fund, L.P. |
542,238 |
|
|
Sanderling Venture Partners IV Co-Investment Fund, L.P. |
224,515 |
|
|
Sanderling Venture Partners V Co-Investment Fund, L.P. |
702,407 |
|
|
Sanderling V Beteiligungs GmbH & Co. KG |
114,536 |
|
|
Sanderling V Limited Partnership |
123,572 |
|
|
Sanderling V Biomedical Co-Investment Fund, L.P. |
412,018 |
|
|
Sanderling Venture Partners II, L.P. |
781,351 |
|
|
Sanderling Management 401(k) Plan |
15,000 |
|
|
Sanderling Venture Partners VI Co-Investment Fund, L.P. |
419,988 |
|
|
Fred A. Middleton |
149,586 |
|
|
Robert G. McNeil |
60,173 |
|
|
Timothy C. Mills |
90,277 |
|
|
Timothy J. Wollaeger |
0 |
|
|
Paul A. Grayson |
0 |
|
|
(ii) Shared power to vote or to direct the vote: |
|
|
Middleton McNeil Retirement Trust |
0 |
|
|
Sanderling Ventures Management V |
0 |
|
|
Sanderling VI Beteiligungs GmbH & Co. KG |
0 |
|
|
Sanderling VI Limited Partnership |
0 |
|
|
Sanderling Ventures Management VI |
0 |
|
|
Sanderling IV Biomedical Co-Investment Fund, L.P. |
0 |
|
|
Sanderling Venture Partners IV Co-Investment Fund, L.P. |
0 |
|
|
Sanderling Venture Partners V Co-Investment Fund, L.P. |
0 |
|
|
Sanderling V Beteiligungs GmbH & Co. KG |
0 |
|
|
Sanderling V Limited Partnership |
0 |
|
|
Sanderling V Biomedical Co-Investment Fund, L.P. |
0 |
|
|
Sanderling Venture Partners II, L.P. |
0 |
|
|
Sanderling Management 401(k) Plan |
0 |
|
|
Sanderling Venture Partners VI Co-Investment Fund, L.P. |
0 |
|
|
Fred A. Middleton |
3,358,107 |
|
|
Robert G. McNeil |
3,358,107 |
|
|
Timothy C. Mills |
1,508,880 |
|
|
Timothy J. Wollaeger |
1,508,880 |
|
|
Paul A. Grayson |
153,209 |
|
|
(iii) Sole power to dispose or to direct the disposition of: |
|
CUSIP No. 85916J102 |
SCHEDULE 13G |
Page 15 of 20 |
|
|
Middleton McNeil Retirement Trust |
797 |
|
|
Sanderling Ventures Management V |
2,724 |
|
|
Sanderling VI Beteiligungs GmbH & Co. KG |
8,128 |
|
|
Sanderling VI Limited Partnership |
9,684 |
|
|
Sanderling Ventures Management VI |
1,149 |
|
|
Sanderling IV Biomedical Co-Investment Fund, L.P. |
542,238 |
|
|
Sanderling Venture Partners IV Co-Investment Fund, L.P. |
224,515 |
|
|
Sanderling Venture Partners V Co-Investment Fund, L.P. |
702,407 |
|
|
Sanderling V Beteiligungs GmbH & Co. KG |
114,536 |
|
|
Sanderling V Limited Partnership |
123,572 |
|
|
Sanderling V Biomedical Co-Investment Fund, L.P. |
412,018 |
|
|
Sanderling Venture Partners II, L.P. |
781,351 |
|
|
Sanderling Management 401(k) Plan |
15,000 |
|
|
Sanderling Venture Partners VI Co-Investment Fund, L.P. |
419,988 |
|
|
Fred A. Middleton |
149,586 |
|
|
Robert G. McNeil |
60,173 |
|
|
Timothy C. Mills |
90,277 |
|
|
Timothy J. Wollaeger |
0 |
|
|
Paul A. Grayson |
0 |
|
|
(iv) Shared power to dispose or to direct the disposition of: |
|
|
Middleton McNeil Retirement Trust |
0 |
|
|
Sanderling Ventures Management V |
0 |
|
|
Sanderling VI Beteiligungs GmbH & Co. KG |
0 |
|
|
Sanderling VI Limited Partnership |
0 |
|
|
Sanderling Ventures Management VI |
0 |
|
|
Sanderling IV Biomedical Co-Investment Fund, L.P. |
0 |
|
|
Sanderling Venture Partners IV Co-Investment Fund, L.P. |
0 |
|
|
Sanderling Venture Partners V Co-Investment Fund, L.P. |
0 |
|
|
Sanderling V Beteiligungs GmbH & Co. KG |
0 |
|
|
Sanderling V Limited Partnership |
0 |
|
|
Sanderling V Biomedical Co-Investment Fund, L.P. |
0 |
|
|
Sanderling Venture Partners II, L.P. |
0 |
|
|
Sanderling Management 401(k) Plan |
0 |
|
|
Sanderling Venture Partners VI Co-Investment Fund, L.P. |
0 |
|
|
Fred A. Middleton |
3,358,107 |
|
|
Robert G. McNeil |
3,358,107 |
|
|
Timothy C. Mills |
1,508,880 |
|
|
Timothy J. Wollaeger |
1,508,880 |
|
|
Paul A. Grayson |
153,209 |
|
Item 5. |
Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following.[ ] |
|
CUSIP No. 85916J102 |
SCHEDULE 13G |
Page 16 of 20 |
|
Item 6. |
Ownership of More than Five Percent on Behalf of Another Person. If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. |
Not applicable
|
Item 7. |
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. |
Not applicable.
|
Item 8. |
Identification and Classification of Members of the Group. If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group. |
Not applicable.
|
Item 9. |
Notice of Dissolution of Group. Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed. If required, by members of the group, in their individual capacity. See Item 5. |
Not applicable.
Item 10. Certifications.
Not applicable.
|
CUSIP No. 85916J102 |
SCHEDULE 13G |
Page 17 of 20 |
Signature
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 14, 2008
Middleton McNeil Retirement Trust
Sanderling Ventures Management V
Sanderling VI Beteiligungs GmbH & Co. KG
Sanderling VI Limited Partnership
Sanderling Ventures Management VI
Sanderling IV Biomedical Co-Investment Fund, L.P.
Sanderling Venture Partners IV Co-Investment Fund, L.P.
Sanderling Venture Partners V Co-Investment Fund, L.P.
|
|
Sanderling V Beteiligungs GmbH & Co. KG |
Sanderling V Limited Partnership
Sanderling V Biomedical Co-Investment Fund, L.P.
Sanderling Venture Partners II, L.P.
Sanderling Management 401(k) Plan
|
|
Sanderling Venture Partners VI Co-Investment Fund, L.P. |
|
By: |
/s/ Fred A. Middleton |
|
|
Fred A. Middelton |
|
|
General Partner |
/s/ Fred A. Middleton
Fred A. Middleton
/s/ Robert G. McNeil
Robert G. McNeil
/s/ Timothy C. Mills
Timothy C. Mills
/s/ Timothy J. Wollaeger
Timothy J. Wollaeger
/s/ Paul A. Grayson
Paul A. Grayson
|
CUSIP No. 85916J102 |
SCHEDULE 13G |
Page 18 of 20 |
JOINT FILING UNDERTAKING
The undersigned, being duly authorized thereunder, hereby execute this agreement as an exhibit to this Schedule 13G to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule jointly on behalf of each such party.
Dated: February 14, 2008
Middleton McNeil Retirement Trust
Sanderling Ventures Management V
Sanderling VI Beteiligungs GmbH & Co. KG
Sanderling VI Limited Partnership
Sanderling Ventures Management VI
Sanderling IV Biomedical Co-Investment Fund, L.P.
Sanderling Venture Partners IV Co-Investment Fund, L.P.
Sanderling Venture Partners V Co-Investment Fund, L.P.
|
|
Sanderling V Beteiligungs GmbH & Co. KG |
Sanderling V Limited Partnership
Sanderling V Biomedical Co-Investment Fund, L.P.
Sanderling Venture Partners II, L.P.
Sanderling Management 401(k) Plan
|
|
Sanderling Venture Partners VI Co-Investment Fund, L.P. |
|
By: |
/s/ Fred A. Middleton |
|
|
Fred A. Middelton |
|
|
General Partner |
/s/ Fred A. Middleton
Fred A. Middleton
/s/ Robert G. McNeil
Robert G. McNeil
/s/ Timothy C. Mills
Timothy C. Mills
/s/ Timothy J. Wollaeger
Timothy J. Wollaeger
/s/ Paul A. Grayson
Paul A. Grayson
|
CUSIP No. 85916J102 |
SCHEDULE 13G |
Page 19 of 20 |
Attachment A
Middleton-McNeil Associates, L.P. is the general partner of Sanderling Venture Partners II, L.P. and has voting and dispositive authority over the shares owned by Sanderling Venture Partners II, L.P. Middleton-McNeil Associates, L.P. is managed by its general partners, Fred A. Middleton and Robert G. McNeil. Such individuals disclaim beneficial ownership of all such shares held by the foregoing funds, except to the extent of their proportionate pecuniary interests therein.
Middleton-McNeil, L.P. is the general partner of Sanderling II Limited Partnership and has voting and dispositive authority over the shares owned by such entities. Middleton-McNeil, L.P. is managed by its general partners, Fred A. Middleton and Robert G. McNeil. Such individuals disclaim beneficial ownership of all such shares held by the foregoing funds, except to the extent of their proportionate pecuniary interests therein.
Middleton-McNeil Associates IV, LLC is the general partner of Sanderling IV Biomedical Co-Investment Fund, L.P. and has voting and dispositive authority over the shares owned by Sanderling IV Biomedical Co-Investment Fund, L.P. Middleton-McNeil Associates IV, LLC is managed by its members, Fred A. Middleton and Robert G. McNeil. Such individuals disclaim beneficial ownership of all such shares held by the foregoing funds, except to the extent of their proportionate pecuniary interests therein.
Middleton-McNeil Associates IV, L.P. is the general partner of Sanderling Venture Partners IV Co-Investment Fund, L.P. and has voting and dispositive power over the shares owned by Sanderling Venture Partners IV Co-Investment Fund, L.P. Middleton-McNeil Associates IV, L.P. is managed by its general partners, Fred A. Middleton and Robert G. McNeil. Such individuals disclaim beneficial ownership of all such shares held by the foregoing funds, except to the extent of their proportionate pecuniary interests therein.
Middleton, McNeil & Mills Associates V, LLC is the Investment General Partner of Sanderling V Limited Partnership and Sanderling V Beteiligungs GmbH & Co. KG and the General Partner of Sanderling V Biomedical Co-Investment Fund, L.P. and Sanderling Venture Partners V Co-Investment Fund, L.P. and has voting and dispositive authority over the shares owned by such entities. Middleton, McNeil & Mills Associates V, LLC is managed by its managing directors, Fred A. Middleton and Robert G. McNeil, Timothy C. Mills and Timothy J. Wollaeger. Such individuals disclaim beneficial ownership of all such shares held by the foregoing funds, except to the extent of their proportionate pecuniary interests therein.
Sanderling Ventures Management V is managed by Fred A. Middleton and Robert G. McNeil, Timothy C. Mills, and Timothy J. Wollaeger, the individuals who have invested under the d/b/a Sanderling Ventures Management V, which individuals have voting and dispositive power over the shares owned by Sanderling Ventures Management V. Such
|
CUSIP No. 85916J102 |
SCHEDULE 13G |
Page 20 of 20 |
individuals disclaim beneficial ownership of all such shares held by the foregoing funds, except to the extent of their proportionate pecuniary interests therein.
Sanderling Ventures Management VI is managed by Fred A. Middleton and Robert G. McNeil, Timothy C. Mills, Timothy J. Wollaeger and Paul A. Grayson, the individuals who have invested under the d/b/a Sanderling Ventures Management VI, which individuals have voting and dispositive power over the shares owned by Sanderling Ventures Management VI. Such individuals disclaim beneficial ownership of all such shares held by the foregoing funds, except to the extent of their proportionate pecuniary interests therein.
Middleton, McNeil, Mills & Associates, VI, LLC is the Investment General Partner of Sanderling Venture Partners VI Co-Investment Fund, L.P., Sanderling VI Beteiligungs GmbH & Co. KG and Sanderling VI Limited Partnership and has voting and dispositive power over the shares owned by such entity. Sanderling Venture Partners VI Co-Investment Fund, L.P. is managed by its managing directors, Fred A. Middleton and Robert G. McNeil, Timothy C. Mills, Timothy J. Wollaeger and Paul A. Grayson. Such individuals disclaim beneficial ownership of all such shares held by the foregoing funds, except to the extent of their proportionate pecuniary interests therein.
The Middleton McNeil Retirement Trust has voting and dispositive authority over the shares owned by such trust. The trust’s trustees are Fred A. Middleton and Robert G., who manage the trust for the benefit of Fred A. Middleton and Robert G. McNeil. Such individuals disclaim beneficial ownership of all such shares held by the foregoing trust, except to the extent of their proportionate pecuniary interests therein.